Deltec Asset Management LLC Reduces Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Deltec Asset Management LLC lowered its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 79.9% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 52,000 shares of the company’s stock after selling 207,246 shares during the period. Deltec Asset Management LLC’s holdings in Xeris Biopharma were worth $115,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its position in shares of Xeris Biopharma by 53.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 27,848 shares of the company’s stock worth $65,000 after purchasing an additional 9,733 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Xeris Biopharma by 351.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 15,973 shares of the company’s stock valued at $38,000 after acquiring an additional 12,432 shares during the period. MPM Bioimpact LLC lifted its position in Xeris Biopharma by 0.3% during the 3rd quarter. MPM Bioimpact LLC now owns 3,987,967 shares of the company’s stock valued at $7,418,000 after acquiring an additional 12,968 shares during the period. Barclays PLC lifted its position in Xeris Biopharma by 14.1% during the 3rd quarter. Barclays PLC now owns 105,743 shares of the company’s stock valued at $197,000 after acquiring an additional 13,040 shares during the period. Finally, SG Americas Securities LLC lifted its position in Xeris Biopharma by 83.9% during the 4th quarter. SG Americas Securities LLC now owns 33,777 shares of the company’s stock valued at $79,000 after acquiring an additional 15,414 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on XERS. Piper Sandler reissued an “overweight” rating and set a $3.00 price target (down from $4.00) on shares of Xeris Biopharma in a research report on Friday, May 10th. Oppenheimer began coverage on shares of Xeris Biopharma in a research report on Thursday, March 28th. They set an “outperform” rating and a $5.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of Xeris Biopharma in a research report on Friday, May 31st.

Xeris Biopharma Stock Down 0.4 %

NASDAQ:XERS traded down $0.01 on Friday, reaching $2.25. 2,849,271 shares of the stock traded hands, compared to its average volume of 1,327,890. The company has a market capitalization of $333.59 million, a price-to-earnings ratio of -4.79 and a beta of 2.68. The company has a current ratio of 2.37, a quick ratio of 1.81 and a debt-to-equity ratio of 49.27. Xeris Biopharma Holdings, Inc. has a 12 month low of $1.46 and a 12 month high of $3.26. The company’s fifty day simple moving average is $2.03 and its 200 day simple moving average is $2.29.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Xeris Biopharma had a negative net margin of 37.58% and a negative return on equity of 16,662.63%. The firm had revenue of $40.64 million for the quarter, compared to the consensus estimate of $41.56 million. Equities analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.